Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsing Multiple Sclerosis: later-stage trial registry
7 of 24 indexed Relapsing Multiple Sclerosis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 7 currently recruiting · #686 of 28,707 conditions by registered trial count
Relapsing Multiple Sclerosis: 24 US clinical trials tracked, 7 recruiting.
Relapsing Multiple Sclerosis is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 17 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 6 of these trials.
Enrollment posture brief
Registry condition relapsing-multiple-sclerosis
OPEN 7 | RECR 29% | LATE 17 | EARLY 3 | RANK #686 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Bleeding (29% recruiting · 24 trials)
Relapsing Multiple Sclerosis lists 7 open slots (29% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsing Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsing Multiple Sclerosis is recruiting below its size-band peers.
7 of 24 indexed trials (29.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Relapsing Multiple Sclerosis research.
Novartis Pharmaceuticals accounts for 6 of 24 trials (25%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Relapsing Multiple Sclerosis enrolment sits around 500 participants.
Median target enrolment is 500 among the 24 trials that report a genuine target (sentinel values excluded). 4 of those (16.7%) plan for fewer than 100 participants.
-
Relapsing Multiple Sclerosis research is mostly interventional.
20 interventional and 4 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics
NCT05877963
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
TG Therapeutics
NCT06433752
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
NCT06846281
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Sandoz
NCT06847724
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04047628
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
University of Colorado, Denver
NCT06529406
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
TG Therapeutics
NCT06143514
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sanofi
NCT06372145
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Novartis Pharmaceuticals
NCT03650114
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
NCT05156281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
NCT05147220
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
NCT04586023
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
NCT04586010
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
NCT05119569
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
Zenas BioPharma (USA)
NCT06564311
Effects of Ocrevus in Relapsing Multiple Sclerosis
Georgia State University
NCT04387734
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
University of California, San Francisco
NCT04466150
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
Biogen
NCT01070836
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Biogen
NCT00906399
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Biogen
NCT01332019
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Novartis Pharmaceuticals
NCT04353492
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Celgene
NCT01628393
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Novartis Pharmaceuticals
NCT03623243
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
Novartis
NCT06395909
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 14 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsing Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsing Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsing Multiple Sclerosis page
24 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Relapsing Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Relapsing Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsing Multiple Sclerosis condition card totals 24 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.